ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1611069
Oxymatrine Inhibited the Progression of Renal Cell Carcinoma by Increasing TOR1AIP1 Expression
Provisionally accepted- 1AFFILIATED HOSPITAL OF SHANDONG SECOND MEDICAL UNIVERSITY, weifang, China
- 2The Affiliated Hospital of Qingdao University, Qingdao, China
- 3Institute of Pain Medicine and Special Environmental Medicine, Co-innovation Center of Neuroregeneration, Nantong University, Nantong, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Aims: The extract of Radix sophorae tonkinensis, known as oxymatrine(OMT), demonstrates anticancer properties. This investigation explored the influence of oxymatrine on renal cell carcinoma (RCC) and elucidated the associated molecular mechanisms, both in vitro and in vivo. Methods: RNA-seq was used to evaluate target genes regulated by OMT. The potential target gene TOR1AIP1 was identified, and the expression of TOR1AIP1 was analyzed in RCC cell lines (Caki-1 and 786-O cells) after treatment with OMT. Further functional assays, including in vitro proliferation, migration, and invasion experiments, were performed. Additionally, overexpression experiments were used to confirm the role of TOR1AIP1 in RCC. In vivo assays using a nude mouse model were conducted to evaluate the effect of OMT on tumor growth. Results: We identified TOR1AIP1 as the potential target gene ofOMT. Among the tested compounds, OMT significantly increased the expression of TOR1AIP1 in RCC cells. OMT inhibited RCC progression, including cell proliferation, migration, and invasion, by upregulating TOR1AIP1. Mechanistically, overexpression of TOR1AIP1 in RCC cells markedly inactivated the JNK signaling pathway and suppressed RCC development. In vivo, OMT treatment significantly inhibited tumor growth, consistent with the in vitro findings. Conclusions: Our findings demonstrate that OMT suppresses RCC progression by increasing the expression of TOR1AIP1 and inactivating the JNK signaling pathway. These findings support TOR1AIP1 as a mechanistic mediator of OMT's antitumor effects in RCC models and provide a rationale for further evaluation in physiologically relevant in vivo systems and with formal pharmacokinetic and toxicity studies.
Keywords: Oxymatrine, TOR1AIP1, Renal cell carcinoma, JNK signaling pathway, therapeutic strategy
Received: 13 Apr 2025; Accepted: 19 Sep 2025.
Copyright: © 2025 Yan, Zhao, Zhang, YIN, Yang, Jiang, He and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Tianzhen He, sailing198562@ntu.edu.cn
Ke Wang, wangke@qdu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.